The promising results obtained inexperimental models of ocular diseases and the recent advancements in theknowledge of the pathogenic mechanisms driving ocular damage and vision lossstrongly point to PPAR-γ as a valuabletarget to control inflammation and treat invalidating diseases such as DR, AMD, and ON. The gene discussed is PPARG; the disease is age-related macular degeneration.